Codexis Inc. (NASDAQ:CDXS) shares, rose in value on Thursday, 05/12/22, with the stock price up by 8.97% to the previous day’s close as strong demand from buyers drove the stock to $10.57.
Actively observing the price movement in the last trading, the stock closed the session at $9.70, falling within a range of $9.47 and $10.85. The value of beta (5-year monthly) was 1.70. Referring to stock’s 52-week performance, its high was $42.01, and the low was $9.61. On the whole, CDXS has fluctuated by -43.90% over the past month.
With the market capitalization of Codexis Inc. currently standing at about $696.77 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.22, which is expected to increase to -$0.09 for fiscal year -$0.38 and then to about -$0.53 by fiscal year 2022. Data indicates that the EPS growth is expected to be 5.00% in 2022, while the next year’s EPS growth is forecast to be -39.50%.
Analysts have estimated the company’s revenue for the quarter at $21.75 million, with a low estimate of $20.7 million and a high estimate of $22.7 million. According to the average forecast, sales growth in current quarter could jump up 3.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $102.03 million, representing an increase of 47.70% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CDXS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
8 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 0 analyst(s), 8 recommend it as a Buy and 0 called the CDXS stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CDXS currently trading nearly -22.22% and -38.83% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.45, while the 7-day volatility ratio is showing 12.06% which for the 30-day chart, stands at 9.31%. Furthermore, Codexis Inc. (CDXS)’s beta value is 1.96, and its average true range (ATR) is 1.17.
A comparison of Codexis Inc. (CDXS) with its peers suggests the former has fared considerably weaker in the market. CDXS showed an intraday change of 8.97% in last session, and over the past year, it shrunk by -39.91%%. In comparison, Balchem Corporation (BCPC) has moved higher at 1.38% on the day and was down -11.58% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has risen 1.90% on the day. The stock, however, is off 25.66% from where it was a year ago. Additionally, there is a loss of -1.16% for Shell plc (SHEL) in last trading while the stock has seen an overall depriciation of 41.34%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.33%.
Data on historical trading for Codexis Inc. (NASDAQ:CDXS) indicates that the trading volumes over the past 10 days have averaged 1.07 million and over the past 3 months, they’ve averaged 781.67K. According to company’s latest data on outstanding shares, there are 64.92 million shares outstanding.
The data on short interest also indicates that stock shorts accounted for 5.1 million shares as on Feb 14, 2022, resulting in a short ratio of 4.64. According to the data, the short interest in Codexis Inc. (CDXS) stood at 7.87% of shares outstanding as of Feb 14, 2022; the number of short shares registered in Jan 13, 2022 reached 8.96 million. The stock has fallen by -66.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CDXS stock heading into the next quarter.